Scarica l'app Stockscreener
7.27
1.22%
-0.09
Precedente Chiudi:
$7.36
Aprire:
$7.48
Volume 24 ore:
612.58K
Relative Volume:
0.55
Capitalizzazione di mercato:
$360.19M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.3821
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-0.41%
1M Prestazione:
-3.96%
6M Prestazione:
-40.46%
1 anno Prestazione:
-60.49%
Intervallo 1D:
$7.22
$7.56
Intervallo di 1 settimana:
$7.22
$7.79
Portata 52W:
$6.56
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.27 | 360.19M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Learn to Evaluate (RGNX) using the Charts - Stock Traders Daily
Goldman Sachs cuts Regenxbio stock rating, slashes price target - MSN
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by SG Americas Securities LLC - Defense World
REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com - Defense World
REGENXBIO (NASDAQ:RGNX) Downgraded to Neutral Rating by The Goldman Sachs Group - MarketBeat
Raymond James Upgrades REGENXBIO (NASDAQ:RGNX) to Moderate Buy - MarketBeat
Goldman Sachs cuts Regenxbio stock rating, slashes price target By Investing.com - Investing.com Australia
Raymond James Begins Coverage on REGENXBIO (NASDAQ:RGNX) - MarketBeat
Goldman Sachs Downgrades REGENXBIO (RGNX) - MSN
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Regenxbio Shares Fall After Downgrade From Goldman Sachs -February 11, 2025 at 02:53 pm EST - Marketscreener.com
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet - MSN
Goldman Sachs Downgrades REGENXBIO to Neutral From Buy, Cuts Price Target to $14 From $38 - Marketscreener.com
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts - Benzinga
REGENXBIO (NASDAQ:RGNX) Research Coverage Started at Raymond James - Defense World
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at StockNews.com - MarketBeat
How To Trade (RGNX) - Stock Traders Daily
Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $34.82 - Armenian Reporter
Raymond James sets $27 target for Regenxbio stock - MSN
The Potential Rise in the Price of Regenxbio Inc (RGNX) following insiders activity - Knox Daily
STATE STREET CORP Reduces Stake in Regenxbio Inc: An In-Depth Analysis - GuruFocus.com
Are Regenxbio Inc (RGNX) shares a good deal now? - US Post News
Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 84%, even after 11% gain this past week - Simply Wall St
Analyzing Ratios: Regenxbio Inc (RGNX)’s Financial Story Unveiled - The Dwinnex
With 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional owners - Yahoo Finance
FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
Vanguard Group Inc Reduces Stake in Regenxbio Inc - GuruFocus.com
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 - PR Newswire
Objective long/short (RGNX) Report - Stock Traders Daily
REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? - MSN
FY2024 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
Analysts Offer Predictions for REGENXBIO FY2029 Earnings - MarketBeat
REGENXBIO’s (RGNX) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
REGENXBIO's (RGNX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership - geneonline
Assenagon Asset Management S.A. Purchases 296,700 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Oct 01 '24 |
Sale |
10.11 |
10,000 |
101,052 |
11,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Option Exercise |
3.76 |
10,000 |
37,600 |
21,286 |
| KARABELAS ARGERIS N | Director |
Sep 03 '24 |
Sale |
11.56 |
10,000 |
115,588 |
11,286 |
| Mills Kenneth T. | Director |
Aug 08 '24 |
Option Exercise |
0.85 |
36,316 |
30,869 |
444,351 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Option Exercise |
3.85 |
10,100 |
38,874 |
21,386 |
| KARABELAS ARGERIS N | Director |
Aug 01 '24 |
Sale |
13.51 |
10,100 |
136,454 |
11,286 |
| Simpson Curran | Chief Executive Officer |
Aug 01 '24 |
Sale |
15.00 |
100 |
1,500 |
170,037 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):